3151 results for «301»
3151 results
Mastering techniques from basic to complex - Advanced TAVI
13 Feb 2026 – From PCR Tokyo Valves 2026
Explore advanced TAVI techniques focusing on challenging patient subsets such as those with small annuli, bicuspid valves, and valve-in-valve procedures. This session reviews valve selection and procedural optimization to enhance clinical outcomes in complex scenarios.
Design that delivers the future of TAVI
13 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses future-oriented TAVI valve design and procedural planning. It highlights supra-annular valve benefits, strategies for managing concomitant coronary artery disease, and redo-TAVI approaches to ensure long-term durability and optimal hemodynamics.
Mastering LAA closure: a step-by-step case experience
14 Feb 2026 – From PCR Tokyo Valves 2026
This session presents a step-by-step, case-based approach to mastering left atrial appendage (LAA) closure. It covers pre-procedural planning, device-specific strategies, complication prevention, and complex bailout techniques such as leak closure with coiling or dual-device implantation.
Patient-tailored treatment for bicuspid valve
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on patient-tailored treatment for bicuspid aortic valve stenosis, providing comprehensive insights into the evidence base for TAVI in this population. It discusses critical considerations for valve selection and sizing, and highlights anatomical features that may pose challenges for TAVI procedures. Case studies illustrate...
Mastering mitral TEER: guidelines, complex cases, and Asia Pacific insights
14 Feb 2026 – From PCR Tokyo Valves 2026
This session provides an in-depth analysis of mitral transcatheter edge-to-edge repair (TEER) in light of the 2025 ESC Valvular Heart Disease guidelines. It addresses optimal timing and treatment strategies for severe heart failure beyond established trials, and explores technical solutions for complex anatomies. Special attention is...
Mitral TEER masterclass
14 Feb 2026 – From PCR Tokyo Valves 2026
This Mitral TEER masterclass focuses on addressing unique anatomical challenges encountered in Asian populations. The session covers device strategies and techniques tailored for complex anatomies, offering practical tips to minimize complications and improve procedural outcomes through detailed case analyses including small hearts, commissural prolapse with calcification,...
Real world outcomes and strategies for optimal TEER across diverse DMR anatomies
14 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the real-world complexities of degenerative mitral regurgitation (DMR) and presents advanced strategies for transcatheter edge-to-edge repair (TEER) using the PASCAL device. Participants will explore the latest registry data, device selection criteria, and tactical approaches to manage diverse and challenging DMR anatomies, aiming...
All you need to know about redo TAVI
15 Feb 2026 – From PCR Tokyo Valves 2026
This comprehensive session addresses the complexities of redo Transcatheter Aortic Valve Implantation (TAVI). It covers the full spectrum from pre-procedural analysis—including coronary obstruction risk and valve sizing—to procedural strategies like leaflet modification and optimal positioning. Post-procedural management including antithrombotic therapy and patient-prosthesis mismatch are also examined,...
The PASCAL IID Registry: A prospective registry for transcatheter edge-to-edge repair in prohibitive risk patients with degenerative mitral regurgitation and complex mitral valve anatomy
17 Sep 2022
Alex Sticchi provides his take on the PASCAL IID Registry and an initial comparison with the CLASP IID. The trial was presented by Jörg Hausleiter during TCT Congress 2022.
Author
Long-term beta-blocker treatment after acute myocardial infarction and preserved left ventricular ejection fraction: The REDUCE-AMI Trial
07 Apr 2024
REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.
Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...
Author
Author
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk
07 Nov 2021
Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...
Author
Author
